Blog
About

1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide.

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A 44-year-old woman with iron deficiency anemia was on a continuous course of intravenous saccharated ferric oxide (SFO). She came to our hospital because of right hip joint pain. She was found to have hypophosphatemia caused by impaired phosphorus resorption and her fibroblast growth factor 23 (FGF-23) levels were elevated. Therefore, she was diagnosed with FGF-23-related osteomalacia due to SFO administration. Discontinuation of the SFO treatment rapidly improved the impaired phosphorus resorption and also normalized the blood levels of phosphorus and FGF-23. During the treatment with SFO, it is important to regularly measure the blood levels of phosphorus in order to prevent the occurrence of osteomalacia.

          Related collections

          Author and article information

          Journal
          Intern. Med.
          Internal medicine (Tokyo, Japan)
          1349-7235
          0918-2918
          2012
          : 51
          : 17
          Affiliations
          [1 ] The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
          Article
          DN/JST.JSTAGE/internalmedicine/51.7450
          22975552

          Comments

          Comment on this article